

Myeloid Malignancies Mutation Panel by Next Generation Sequencing

Patient:		Client:	ARUP Test Code: 2011117
DOB: Age: 48	Sex: M		
Patient Identifiers:			Collection Date: 09/16/2024
		Physician: Doctor Unknown	Received in lab: 09/19/2024
Visit Number (FIN):			Completion Date: 09/30/2024
			,

Comment:

Submitted diagnosis or diagnosis under consideration for variant interpretation: Thrombocytopenia

None Detected							
Gene	Transcript ID	DNA Variant	Protein Variant	Variant Frequency			
TIER 2:	Variants of Unk	nown Clinical Signifi	cance in Hematologic Mali	gnancies			
None Det	ected						
Gene	Transcript ID	DNA Variant	Protein Variant	Variant Frequency			
TIER 1:	Variants of Know	wn Clinical Significa	nce in Hematologic Maligna	ancies			

Listed below are regions where the average sequencing depth (number of times a particular nucleotide is sequenced) in at least 20% of the region-of-interest is less than our stringent cutoff of 300. Sensitivity for detection of low allelic frequency variants may be reduced in areas with reduced depth of coverage.

None

This result has been reviewed and approved by



Patient: ARUP Accession: 24-260-158713 Patient: Patient Identifiers: | Date of Birth: Visit Number (FIN): | Sex: M | Physician: Doctor Unknown

BACKGROUND INFORMATION: Myeloid Malignancies Mutation

Panel by Next Generation Sequencing

CHARACTERISTICS: Myeloid malignancies are clonal disorders of hematopoietic stem and progenitor cells that include myelodysplastic syndromes (MDSs), myeloproliferative neoplasms (MPNs), myelodysplastic/myeloproliferative neoplasms (MDS/MPNs), and acute myeloid leukemia (AML). Recent studies have identified recurrently mutated genes with diagnostic and/or prognostic impact in myeloid malignancies. The presence of certain mutations may inform clinical management. This multigene panel by massively parallel sequencing (next generation sequencing) is a more cost-effective approach when compared to the cost of multiple single gene tests. This test can be used to complement the morphologic and cytogenetic workup of myeloid malignancies.

GENES TESTED: ANKRD26; ASXL1; ASXL2; BCOR; BCORL1; BRAF; CALR; CBL; CBLB; CEBPA; CSF3R; CUX1*; DDX41; DNMT1*; DNMT3A; ELANE; ETNK1; ETV6; EZH2; FBXW7; FLT3; GATA1; GATA2; GNAS; HNRNPK; IDH1; IDH2; IL7R; JAK1; JAK2; JAK3; KDM6A*; KIT; KMT2A; KRAS; LUC7L2; MPL; NOTCH1; NPM1*; NRAS; NSD1; PHF6; PIGA; PPM1D; PRPF40B; PRPF8; PTPN11; RAD21; RUNX1; SAMD9; SAMD9L; SETBP1; SF3B1; SH2B3; SMC1A; SMC3; SRSF2; STAG2; STAT3; STAT5B*; SUZ12*; TET2; TP53; U2AF1; U2AF2; UBA1; WT1; ZRSR2.

*One or more exons of the preferred transcript were not covered by sequencing for the indicated gene; see limitations section below.

METHODOLOGY: Genomic DNA was isolated from peripheral blood or bone marrow and then enriched for the targeted exonic regions of the tested genes. The variant status of the targeted genes was determined by massively parallel sequencing. The hg19 (GRCh37) human genome assembly was used as a reference for identifying genetic variants. Clinically significant variants and variants of uncertain significance called in the preferred transcript are reported.

LIMITATIONS: Variants outside the targeted regions or below the limit of detection are not identified. Variants in regions that are not included in the preferred transcript for the targeted genes are not detected. In some cases, variants may not be identified due to technical limitations in the presence of pseudogenes or in repetitive or homologous regions. It is also possible some insertion/deletion variants may not be identified. Benign or likely benign variants in the preferred transcript are not reported. The following regions were not sequenced due to technical limitations of the assay:

CUX1 (NM_181552) exon 24 DNMT1 (NM_001130823) exon 5 KDM6A (NM_001291415) exon 13 NPM1 (NM_002520) exon 1 STAT5B (NM_012448) exons 6-9 SUZ12 (NM_015355) exons 1-9


LIMIT OF DETECTION (LOD): 5 percent variant allele fraction (VAF) for single nucleotide variants (SNV) and small variants less than 24 base pairs (bp). Variants greater than 24bp may be detected at LOD, but the analytical sensitivity may be reduced.

ANALYTICAL SENSITIVITY: The positive percent agreement (PPA) estimate for the respective variant classes (with95 percent credibility region) are listed below. Genes included on this test are a subset of a larger methods-based validation from which the PPA values are derived.

Single nucleotide variants (SNVs): 96.9 percent (95.1-98.1 percent) Insertions/duplications (1-24bp): 98.1 percent (95.5-99.3 percent) Insertions/duplications (greater than 24bp): greater than 99 percent (92.9-100.0 percent) Deletions (1-24bp): 96.7 percent (92.8-98.7 percent) Deletions (greater than 24bp): 90 percent (79.5-96.1 percent) Multinucleotide variants (MNVs): 97 percent (93.0-99.0 percent) FLT3 ITDs: Greater than 99 percent (97.1-100.0 percent)

CLINICAL DISCLAIMER: Results of this test must always be interpreted within the context of clinical findings and other relevant data and should not be used alone for a diagnosis of malignancy. This test is not intended to detect minimal residual disease.

This test was developed and its performance characteristics determined by ARUP Laboratories. It has not been cleared or approved by the U.S. Food and Drug Administration. This test was performed in a CLIA-certified laboratory and is intended for clinical purposes.



ARUP LABORATORIES | 800-522-2787 | aruplab.com 500 Chipeta Way, Salt Lake City, UT 84108-1221 Jonathan R. Genzen, MD, PhD, Laboratory Director Patient: ARUP Accession: 24-260-158713